Anti-SELPLG ADCC Enhanced Antibody (AbGn-168) is an ADCC enhanced antibody produced by our Afuco™ platform. AbGn-168H is a humanized monoclonal antibody being developed to treat inflammatory diseases, has been demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Due to the unique mechanism of action, AbGn-168H has potential benefit for treating multiple immune-related diseases.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-555CL | Human Anti-SELPLG Recombinant Antibody (TAB-555CL) | ELISA | Human IgG |
There are currently no Customer reviews or questions for AFC-533CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.